TY - JOUR
T1 - Serum Potassium and Risk of Death or Kidney Replacement Therapy in Older People With CKD Stages 4-5
T2 - Eight-Year Follow-up
AU - de Rooij, Esther N. M.
AU - de Fijter, Johan W.
AU - le Cessie, Saskia
AU - Hoorn, Ewout J.
AU - Jager, Kitty J.
AU - Chesnaye, Nicholas C.
AU - Evans, Marie
AU - Windahl, Karin
AU - Caskey, Fergus J.
AU - Torino, Claudia
AU - Szymczak, Maciej
AU - Drechsler, Christiane
AU - Wanner, Christoph
AU - Dekker, Friedo W.
AU - Hoogeveen, Ellen K.
AU - Schneider, Andreas
AU - Torp, Anke
AU - Iwig, Beate
AU - Perras, Boris
AU - Marx, Christian
AU - Blaser, Christof
AU - Emde, Claudia
AU - Krieter, Detlef
AU - Fuchs, Dunja
AU - Irmler, Ellen
AU - Platen, Eva
AU - Schmidt-Gürtler, Hans
AU - Schlee, Hendrik
AU - Naujoks, Holger
AU - Schlee, Ines
AU - Cäsar, Sabine
AU - Beige, Joachim
AU - Röthele, Jochen
AU - Mazur, Justyna
AU - Hahn, Kai
AU - Blouin, Katja
AU - Neumeier, Katrin
AU - Anding-Rost, Kirsten
AU - Schramm, Lothar
AU - Hopf, Monika
AU - Wuttke, Nadja
AU - Frischmuth, Nikolaus
AU - Ichtiaris, Pawlos
AU - Kirste, Petra
AU - Schulz, Petra
AU - Aign, Sabine
AU - Biribauer, Sandra
AU - Manan, Sherin
AU - Röser, Silke
AU - Heidenreich, Stefan
AU - Palm, Stephanie
AU - Schwedler, Susanne
AU - Delrieux, Sylke
AU - Renker, Sylvia
AU - Schättel, Sylvia
AU - Stephan, Theresa
AU - Schmiedeke, Thomas
AU - Weinreich, Thomas
AU - Leimbach, Til
AU - Stövesand, Torsten
AU - Bahner, Udo
AU - Seeger, Wolfgang
AU - Cupisti, Adamasco
AU - Sagliocca, Adelia
AU - Ferraro, Alberto
AU - Mele, Alessandra
AU - Naticchia, Alessandro
AU - Còsaro, Alex
AU - Ranghino, Andrea
AU - Stucchi, Andrea
AU - Pignataro, Angelo
AU - de Blasio, Antonella
AU - Pani, Antonello
AU - Tsalouichos, Aris
AU - Antonio, Bellasi
AU - Alessandra, Butti
AU - Abaterusso, Cataldo
AU - Somma, Chiara
AU - D'alessandro, Claudia
N1 - Funding Information: Main funding for the EQUAL study was received from the European Renal Association and contributions from the Swedish Medical Association, the Stockholm County Council ALF Medicine and Center for Innovative Research, the Italian Society of Nephrology, the Dutch Kidney Foundation, the Young Investigators Grant in Germany, and the National Institute for Health Research in the United Kingdom. The funders had no role in the study design, data collection, analysis, reporting, or the decision to submit the manuscript for publication. Publisher Copyright: © 2023 The Authors
PY - 2023/9
Y1 - 2023/9
N2 - Rationale & Objective: Hypokalemia may accelerate kidney function decline. Both hypo- and hyperkalemia can cause sudden cardiac death. However, little is known about the relationship between serum potassium and death or the occurrence of kidney failure requiring replacement therapy (KRT). We investigated this relationship in older people with chronic kidney disease (CKD) stage 4-5. Study Design: Prospective observational cohort study. Setting & Participants: We followed 1,714 patients (≥65 years old) from the European Quality (EQUAL) study for 8 years from their first estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73 m2 measurement. Exposure: Serum potassium was measured every 3 to 6 months and categorized as ≤3.5, >3.5-≤4.0, >4.0-≤4.5, >4.5-≤5.0 (reference), >5.0-≤5.5, >5.5-≤6.0, and >6.0 mmol/L. Outcome: The combined outcome death before KRT or start of KRT. Analytical Approach: The association between categorical and continuous time-varying potassium and death or KRT start was examined using Cox proportional hazards and restricted cubic spline analyses, adjusted for age, sex, diabetes, cardiovascular disease, renin-angiotensin-aldosterone system (RAAS) inhibition, eGFR, and subjective global assessment (SGA). Results: At baseline, 66% of participants were men, 42% had diabetes, 47% cardiovascular disease, and 54% used RAAS inhibitors. Their mean age was 76 ± 7 (SD) years, mean eGFR was 17 ± 5 (SD) mL/min/1.73 m2, and mean SGA was 6.0 ± 1.0 (SD). Over 8 years, 414 (24%) died before starting KRT, and 595 (35%) started KRT. Adjusted hazard ratios for death or KRT according to the potassium categories were 1.6 (95% CI, 1.1-2.3), 1.4 (95% CI, 1.1-1.7), 1.1 (95% CI, 1.0-1.4), 1 (reference), 1.1 (95% CI, 0.9-1.4), 1.8 (95% CI, 1.4-2.3), and 2.2 (95% CI, 1.5-3.3). Hazard ratios were lowest at a potassium of about 4.9 mmol/L. Limitations: Shorter intervals between potassium measurements would have allowed for more precise estimations. Conclusions: We observed a U-shaped relationship between serum potassium and death or KRT start among patients with incident CKD 4-5, with a nadir risk at a potassium level of 4.9 mmol/L. These findings underscore the potential importance of preventing both high and low potassium in patients with CKD 4-5. Plain-Language Summary: Abnormal potassium blood levels may increase the risk of death or kidney function decline, especially in older people with chronic kidney disease (CKD). We studied 1,714 patients aged ≥65 years with advanced CKD from the European Quality (EQUAL) study and followed them for 8 years. We found that both low and high levels of potassium were associated with an increased risk of death or start of kidney replacement therapy, with the lowest risk observed at a potassium level of 4.9 mmol/L. In patients with CKD, the focus is often on preventing high blood potassium. However, this relatively high optimum potassium level stresses the potential importance of also preventing low potassium levels in older patients with advanced CKD.
AB - Rationale & Objective: Hypokalemia may accelerate kidney function decline. Both hypo- and hyperkalemia can cause sudden cardiac death. However, little is known about the relationship between serum potassium and death or the occurrence of kidney failure requiring replacement therapy (KRT). We investigated this relationship in older people with chronic kidney disease (CKD) stage 4-5. Study Design: Prospective observational cohort study. Setting & Participants: We followed 1,714 patients (≥65 years old) from the European Quality (EQUAL) study for 8 years from their first estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73 m2 measurement. Exposure: Serum potassium was measured every 3 to 6 months and categorized as ≤3.5, >3.5-≤4.0, >4.0-≤4.5, >4.5-≤5.0 (reference), >5.0-≤5.5, >5.5-≤6.0, and >6.0 mmol/L. Outcome: The combined outcome death before KRT or start of KRT. Analytical Approach: The association between categorical and continuous time-varying potassium and death or KRT start was examined using Cox proportional hazards and restricted cubic spline analyses, adjusted for age, sex, diabetes, cardiovascular disease, renin-angiotensin-aldosterone system (RAAS) inhibition, eGFR, and subjective global assessment (SGA). Results: At baseline, 66% of participants were men, 42% had diabetes, 47% cardiovascular disease, and 54% used RAAS inhibitors. Their mean age was 76 ± 7 (SD) years, mean eGFR was 17 ± 5 (SD) mL/min/1.73 m2, and mean SGA was 6.0 ± 1.0 (SD). Over 8 years, 414 (24%) died before starting KRT, and 595 (35%) started KRT. Adjusted hazard ratios for death or KRT according to the potassium categories were 1.6 (95% CI, 1.1-2.3), 1.4 (95% CI, 1.1-1.7), 1.1 (95% CI, 1.0-1.4), 1 (reference), 1.1 (95% CI, 0.9-1.4), 1.8 (95% CI, 1.4-2.3), and 2.2 (95% CI, 1.5-3.3). Hazard ratios were lowest at a potassium of about 4.9 mmol/L. Limitations: Shorter intervals between potassium measurements would have allowed for more precise estimations. Conclusions: We observed a U-shaped relationship between serum potassium and death or KRT start among patients with incident CKD 4-5, with a nadir risk at a potassium level of 4.9 mmol/L. These findings underscore the potential importance of preventing both high and low potassium in patients with CKD 4-5. Plain-Language Summary: Abnormal potassium blood levels may increase the risk of death or kidney function decline, especially in older people with chronic kidney disease (CKD). We studied 1,714 patients aged ≥65 years with advanced CKD from the European Quality (EQUAL) study and followed them for 8 years. We found that both low and high levels of potassium were associated with an increased risk of death or start of kidney replacement therapy, with the lowest risk observed at a potassium level of 4.9 mmol/L. In patients with CKD, the focus is often on preventing high blood potassium. However, this relatively high optimum potassium level stresses the potential importance of also preventing low potassium levels in older patients with advanced CKD.
KW - Chronic kidney disease
KW - death
KW - elderly
KW - end-stage kidney disease
KW - kidney replacement therapy
KW - mortality
KW - potassium
UR - http://www.scopus.com/inward/record.url?scp=85163842842&partnerID=8YFLogxK
U2 - https://doi.org/10.1053/j.ajkd.2023.03.008
DO - https://doi.org/10.1053/j.ajkd.2023.03.008
M3 - Article
C2 - 37182596
SN - 0272-6386
VL - 82
SP - 257-266.e1
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 3
ER -